Estudiado en personas
Existen estudios publicados en personas. No es un medicamento autorizado en Estados Unidos ni en la Unión Europea.
Esta página es un esbozo
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
Qué tan sólida es la evidencia
Hasta dónde ha llegado
Todo medicamento sube la misma escalera. La mayoría de los compuestos nunca llega a lo más alto, y el lugar que ocupa indica cuánto pueden sostener sus afirmaciones.
- Medicamento autorizado
Un regulador ha revisado los ensayos y lo ha autorizado para un uso concreto.
- Fase 3
Ensayos aleatorizados grandes, a menudo con miles de personas, frente a placebo o un tratamiento estándar.
- Fase 2
Ensayos de tamaño medio que miden la dosis frente al efecto en personas con la enfermedad.
- Fase 1 y estudios humanos iniciales: ARA-290
Primeros estudios en personas: seguridad y cómo el organismo lo procesa.
- Células y animales
Trabajo de laboratorio y con animales. Un resultado en animales no es un resultado en personas.
- 77
- artículos en PubMed
- 37
- de ellos en personas
- 4
- ensayos aleatorizados
- 14
- revisiones
Un recuento indica cuánto se ha publicado, no lo que encontró. Contado en PubMed: 2026-11-16
Manipulación y reconstitución
Del polvo a una muestra medida
Los mismos cuatro pasos para cualquier vial liofilizado. Manipulación de laboratorio, no uso en una persona.
1. Lea el vial
La etiqueta indica la masa de péptido en el vial, en miligramos. Ese número es el punto de partida de todo cálculo.
2. Añada el diluyente
Se añade un volumen medido de diluyente lentamente, por la pared del vidrio. Haga girar con suavidad; agitar puede dañar un péptido.
3. Calcule la concentración
La concentración es la masa dividida por el volumen: 10 mg en 2 mL son 5 mg por mL.
4. Mida la muestra
El volumen es la masa deseada dividida por la concentración. En una jeringa U-100, 1 mL equivale a 100 unidades.
La calculadora de abajo hace la aritmética y muestra el procedimiento.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on ARA-290 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of ARA-290; no amount here is a recommendation.
ARA-290: en PubMed
What PubMed held for ARA-290 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 77
- papers
- 37
- in humans
- 5
- clinical trials
- 4
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- The time to develop treatments for diabetic neuropathy
ReviewRendell MS Expert opinion on investigational drugs, 2021. PMID 33423557
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
Randomized trialCulver DA, Dahan A, Bajorunas D, et al. Investigative ophthalmology & visual science, 2017. PMID 28475703
- Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action
Randomized trialCerit H, Veer IM, Dahan A, et al. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015. PMID 26431906
- Managing fatigue in sarcoidosis - A systematic review of the evidence
ReviewAtkins C, Wilson AM Chronic respiratory disease, 2017. PMID 27507833
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Randomized trialDahan A, Dunne A, Swartjes M, et al. Molecular medicine (Cambridge, Mass.), 2013. PMID 24136731
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Randomized trialHeij L, Niesters M, Swartjes M, et al. Molecular medicine (Cambridge, Mass.), 2012. PMID 23168581
- Multifaceted roles of a bioengineered nanoreactor in repressing radiation-induced lung injury
StudyLiu T, Yang Q, Zheng H, et al. Biomaterials, 2021. PMID 34478930
- Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus
StudyHuang B, Jiang J, Luo B, et al. Journal of cellular and molecular medicine, 2018. PMID 29570934
Search used: ("ARA 290"[tiab] OR "ARA290"[tiab] OR cibinetide[tiab]). Run it on PubMed
Enlaces de investigación
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for ARA-290 on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.